Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities

v3.24.1
Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Net operating losses carry forward $ 41,698 $ 44,233
Deferred revenue 8,219
Share-based compensation 1,512 1,334
Research and development/orphan drug credits 20,509 17,247
Capitalized research and development expenses 18,684 13,210
Others (57) 69
Less: valuation allowance (90,566) (76,093)
Deferred tax assets, net